These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 34670840)

  • 1. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.
    Regierer AC; Hasseli R; Schäfer M; Hoyer BF; Krause A; Lorenz HM; Pfeil A; Richter J; Schmeiser T; Schulze-Koops H; Strangfeld A; Voll RE; Specker C; Mueller-Ladner U
    RMD Open; 2021 Oct; 7(3):. PubMed ID: 34670840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
    Sparks JA; Wallace ZS; Seet AM; Gianfrancesco MA; Izadi Z; Hyrich KL; Strangfeld A; Gossec L; Carmona L; Mateus EF; Lawson-Tovey S; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Pons-Estel GJ; Isnardi CA; Berbotto GA; Hsu TY; D'Silva KM; Patel NJ; Kearsley-Fleet L; Schäfer M; Ribeiro SLE; Al Emadi S; Tidblad L; Scirè CA; Raffeiner B; Thomas T; Flipo RM; Avouac J; Seror R; Bernardes M; Cunha MM; Hasseli R; Schulze-Koops H; Müller-Ladner U; Specker C; Souza VA; Mota LMHD; Gomides APM; Dieudé P; Nikiphorou E; Kronzer VL; Singh N; Ugarte-Gil MF; Wallace B; Akpabio A; Thomas R; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Yazdany J;
    Ann Rheum Dis; 2021 Sep; 80(9):1137-1146. PubMed ID: 34049860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
    Gianfrancesco M; Hyrich KL; Al-Adely S; Carmona L; Danila MI; Gossec L; Izadi Z; Jacobsohn L; Katz P; Lawson-Tovey S; Mateus EF; Rush S; Schmajuk G; Simard J; Strangfeld A; Trupin L; Wysham KD; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Wallace ZS; Yazdany J; Machado PM; Robinson PC;
    Ann Rheum Dis; 2020 Jul; 79(7):859-866. PubMed ID: 32471903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.
    Kroon FPB; Najm A; Alunno A; Schoones JW; Landewé RBM; Machado PM; Navarro-Compán V
    Ann Rheum Dis; 2022 Mar; 81(3):422-432. PubMed ID: 34876462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients.
    FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors
    Ann Rheum Dis; 2021 Apr; 80(4):527-538. PubMed ID: 33268442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
    Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases.
    Hasseli R; Mueller-Ladner U; Hoyer BF; Krause A; Lorenz HM; Pfeil A; Richter J; Schäfer M; Schmeiser T; Strangfeld A; Schulze-Koops H; Voll RE; Specker C; Regierer AC
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33479021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.
    Andreica I; Blazquez-Navarro A; Sokolar J; Anft M; Kiltz U; Pfaender S; Vidal Blanco E; Westhoff T; Babel N; Stervbo U; Baraliakos X
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36104115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
    Strangfeld A; Schäfer M; Gianfrancesco MA; Lawson-Tovey S; Liew JW; Ljung L; Mateus EF; Richez C; Santos MJ; Schmajuk G; Scirè CA; Sirotich E; Sparks JA; Sufka P; Thomas T; Trupin L; Wallace ZS; Al-Adely S; Bachiller-Corral J; Bhana S; Cacoub P; Carmona L; Costello R; Costello W; Gossec L; Grainger R; Hachulla E; Hasseli R; Hausmann JS; Hyrich KL; Izadi Z; Jacobsohn L; Katz P; Kearsley-Fleet L; Robinson PC; Yazdany J; Machado PM;
    Ann Rheum Dis; 2021 Jul; 80(7):930-942. PubMed ID: 33504483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
    Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
    JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.
    Sengler C; Eulert S; Minden K; Niewerth M; Horneff G; Kuemmerle-Deschner J; Siemer C; Berendes R; Girschick H; Hühn R; Borte M; Hospach A; Emminger W; Armann J; Klein A; Kallinich T
    RMD Open; 2021 Jul; 7(2):. PubMed ID: 34312307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
    Montero F; Martínez-Barrio J; Serrano-Benavente B; González T; Rivera J; Molina Collada J; Castrejón I; Álvaro-Gracia J
    Rheumatol Int; 2020 Oct; 40(10):1593-1598. PubMed ID: 32794113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Immunosuppressive or Immunomodulatory Agents on Severe COVID-19 Outcomes: A Population-Based Cohort Study.
    Marozoff S; Tan J; Lu N; Kirmani A; Loree JM; Xie H; Lacaille D; Kopec JA; Esdaile JM; Corradetti B; Malone P; Koehn CL; Mennell P; Hoens AM; Aviña-Zubieta JA
    ACR Open Rheumatol; 2023 Dec; 5(12):685-693. PubMed ID: 37818772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response after SARS-CoV-2 vaccination in patients with inflammatory immune-mediated diseases receiving immunosuppressive treatment.
    Plasencia-Rodríguez C; Martínez-Feito A; Hernández M; Del Pino-Molina L; Novella-Navarro M; Serrano Y; González-Muñoz M; Peiteado D; Bonilla G; Monjo I; Nuño L; Tornero C; López-Granados E; Balsa A; Nozal P
    Allergy Asthma Clin Immunol; 2023 Aug; 19(1):71. PubMed ID: 37598192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States.
    Raiker R; DeYoung C; Pakhchanian H; Ahmed S; Kavadichanda C; Gupta L; Kardeş S
    Semin Arthritis Rheum; 2021 Oct; 51(5):1057-1066. PubMed ID: 34450504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.
    Farisogullari B; Lawson-Tovey S; Hyrich KL; Gossec L; Carmona L; Strangfeld A; Mateus EF; Schäfer M; Rodrigues A; Hachulla E; Gomez-Puerta JA; Mosca M; Durez P; Trefond L; Goulenok T; Cornalba M; Stenova E; Bulina I; Strakova E; Zepa J; Roux N; Brocq O; Veillard E; Raffeiner B; Burmester GR; Mariette X; Machado PM;
    Ann Rheum Dis; 2024 Oct; 83(11):1584-1595. PubMed ID: 38816065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe COVID-19 in patients with immune-mediated rheumatic diseases: A stratified analysis from the SORCOM multicentre registry.
    Boteanu A; Leon L; Pérez Esteban S; Rabadán Rubio E; Pavía Pascual M; Bonilla G; Bonilla González-Laganá C; García Fernandez A; Recuero Diaz S; Ruiz Gutierrez L; Sanmartín Martínez JJ; de la Torre-Rubio N; Nuño L; Sánchez Pernaute O; Del Bosque I; Lojo Oliveira L; Rodríguez Heredia JM; Clemente D; Abasolo L; Bachiller-Corral J
    Mod Rheumatol; 2023 Dec; 34(1):97-105. PubMed ID: 36516217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.